Subjects n | 154 |
Demographics | |
Age years | 12.6±3.3 (6–18) |
Male sex n (%) | 76 (49%) |
Hb genotype n (%) | |
HbSS | 106 (69%) |
HbSC | 34 (22%) |
HbSB+thal | 9 (6%) |
HbSBothal | 4 (3%) |
HbSE | 1 (1%) |
History of ACS n (%) | 56 (36%) |
Pulmonary function testing |
FVC % predicted | 86.7±14.0 (53–127) |
FEV1 % predicted | 84.8±15.0 (48–118) |
FEV1/FVC % | 86.1±6.1 (64–98) |
FEF25–75 % predicted | 84.4±29.9 (31–261) |
12% change in FEV1 or FVC n (%) | 20 (13%) |
30% change in FEF25–75 n (%) | 46 (30%) |
ISAAC questionnaires# |
Physician diagnosis of asthma n (%) | 24 (22%) |
History of ever having wheezed n (%) | 42 (39%) |
History of recent wheezing n (%) | 21 (19%) |
Airway nitric oxide measurements¶ |
Fractional exhaled nitric oxide ppb | 17.9±15.9 (2–102) |
Nasal nitric oxide ppb | 890±387 (16–3146) |
Rate of decline in FEV1/FVC+ |
History of recent wheezing % (95% CI) | 0.90 (0.61–1.19) |
No history of recent wheezing % (95% CI) | 0.33 (0.22–0.44) |